LYFT vs RXRX · P/E 108, rev $5.79B vs rev $58.8M
LYFT Inc (LYFT) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
LYFT Inc (LYFT) is a software - application company listed on US. It is led by David Risher.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported LYFT revenue for 2024-12-31 was $5.79B. Net income was $22.8M. Revenue was up 31.4% from 2023-12-31 to 2024-12-31. LYFT currently screens at market cap $6.79B and trailing P/E 107.7.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
LYFT currently screens at market cap $6.79B and trailing P/E 107.7. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the LYFT and RXRX stock pages for the full models.
Not investment advice.